Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Tesla board floats $1trn pay package for Elon Musk

(Sharecast News) - Electric carmaker Tesla has proposed a landmark compensation package for chief executive Elon Musk, potentially worth as much as $1trn over the next decade. The pay package, which was contingent on a series of performance milestones, including the expansion of its robotaxi business and a near ninefold increase in market valuation, would see Musk rewarded incrementally as Tesla's market cap climbs from its current $1trn level to $8.5trn.

Musk's proposed payout also echoes his 2018 package, which catalysed Tesla's surge to tech mega-cap status, but dwarfs it in scope and ambition.

If approved, the package would cement Musk's status as the highest-paid executive in corporate history, while signalling Tesla's intent to dominate the next phase of autonomous transport.

AJ Bell's Dan Coatsworth said: "Tesla is a public company, and shareholders will ultimately decide if he deserves a $1trn pay deal. Securing this money will be dependent on hitting targets and current progress suggests Musk will need a stroke of extraordinarily good luck to grab the 13-digit figure. Shareholders would love for Musk to hit the targets to trigger the payday, as they would also share in the success via a higher share price. Therefore, it feels like many investors would happily approve it.

"The bigger question is whether this proposal sets a new precedent and boardrooms across America will think it's ok to add a zero or two onto the end of current remuneration packages. It all seems a tad excessive and a symptom of poor corporate governance."

As of 1345 BST, Tesla shares were up 1.93% at $345.08 each.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.